Table 1 Overview of the studies published by authors consulted when planning the IPD meta-analysis
Study | Period | N | Intervention | Primary outcome |
|---|---|---|---|---|
Briery[11] | 06/04-06/10 | 30 | 250 mg 17-OPHC or placebo | delivery before 35 completed weeks' of gestation |
Cetingoz[10] | 12/04-02/07 | 67 | 100 mg vaginal progesterone or placebo | delivery before 37 weeks |
Lim[12] | 08/06-07/09 | 654 | 250 mg 17-OHPC in 1 mL castor oil or placebo | composite outcome (Severe RDS, BPD, IVH grade III or worse, NEC, proven sepsis or death before discharge) |
Combs[7] | 11/04-02/10 | 240 | 250 mg 17-OHPC or placebo | composite outcome (RDS, Oxygen therapy at 28d, Neonatal sepsis, Pneumonia, IVH grade III or worse, periventricular leukomalacia, NEC, retinopathy of prematurity, asphyxia) |
Nassar[13] | 10/06-10/10 | 290 | 250 mg 17-OPHC or placebo | frequency of delivery prior to completed 37 weeks of gestation (259 days) |
Norman[9] | 12/04-04/08 | 500 | Vaginal progesterone gel 90 mg or placebo | delivery or intrauterine death before 34 weeks of gestation |
Rode[14] | 06/06-09/10 | 650 | 200 mg vaginal progesterone of placebo | incidence of delivery < 34 weeks |
Rouse[8] | 04/04-02/06 | 661 | 250 mg 17-OHPC in 1 mL castor oil or placebo | composite outcome (delivery or fetal death before 35 completed weeks of gestation) |
Rozenberg[15] | 06/06-06/10 | 160 | 500 mg 17-OPHC or no treatment | Interval between inclusion and delivery |
Serra[16] | 01/06-05/08 | 246 | 200 mg or 400 mg vaginal progesterone or placebo | Preterm birth rate (< 37 weeks) |